Press

Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp.

Jan 21 • 8 min read

Eleusis, a clinical-stage life science company that aims to unlock the therapeutic potential of psychedelics, and Silver Spike Acquisition Corp. II (NASDAQ: SPKB) a publicly traded special purpose acquisition company sponsored by an affiliate of Silver Spike Capital (“Silver Spike”), announced today that they have signed a definitive business combination agreement expected to make Eleusis…

BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder Treatment

Jan 20 • 3 min read

BetterLife Pharma Inc. (CSE: BETR OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd-generation non-hallucinogenic psychedelic analogs for the treatment of neuropsychological disorders, is pleased to announce it has received a written response from the U.S. Food and Drug Administration (FDA) to its pre-investigational new drug (pre-IND) application for the treatment…

Nucleus, a Data-Driven Psychedelics Platform, Begins to Orbit the Mental Health Crisis; Logan Lenz to Captain the Ship

Jan 19 • 4 min read

Nucleus, a South Florida startup focused on mental health data and technologies, today announced its launch. The company, which is wholly owned by the venture capital firm, Iter Investments, is unveiling an entire ecosystem designed to meet people where they are and support them on their mental health journey. The platform is centered around a unique search…

Survey Finds Majority of Affected Americans Approve of Psychedelics as an Alternative Treatment to Address Anxiety, Depression and PTSD

Jan 19 • 4 min read

A new survey conducted by The Harris Poll on behalf of Delic Holdings Corp (CSE: DELC) (OTCQB: DELCF) (Original Source), a leader in new medicines and treatments for a modern world, reports that nearly two thirds of Americans who suffer from anxiety/depression/PTSD (65%) believe that psychedelic medicine (i.e. ketamine, psilocybin and MDMA) should be made available to patients…

MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

Jan 14 • 3 min read

MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced that it has entered into Collaborative Research Agreement (the “Agreement”) with the University of British Columbia (“UBC”) focussing on Novel Therapies for Neurological Diseases. MYND is creating safe and effective precision medicines…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441